Advertisement

Conference Coverage for the ACR/ARHP Annual Meeting

Quick Links

The 2018 ACR/ARHP Annual Meeting was held October 19 – 24 in Chicago, Illinois. The American College of Rheumatology’s Annual Meeting features over 450 sessions on the latest in rheumatology research and clinical applications.

This website summarizes just a few of those sessions that we thought would be of particular interest to those involved in managed care pharmacy.

Study Finds Possible Overlooked Risk Factor for Heart Attack

New study results presented at the annual meeting suggest that immunoglobulin G4 (IgG) antiphospholipid antibody positivity may be an important but overlooked risk factor for myocardial infarction (MI).

Study Finds That Intensity of Walking Affects Risk of Knee Replacement

Patients with knee osteoarthritis (OA) who walk with moderate to vigorous intensity may lower their risk of total knee arthroplasty (TKA), according to new research presented at the annual meeting.

Associations Jointly Present Draft of First Classification Criteria for IgG4-related Disease

The American College of Rheumatology (ACR) and European League Against Rheumatism have presented a draft of “Classification Criteria for IgG4-related Disease,” the first classification criteria developed for the recently recognized disease. The criteria were unveiled during a session at the annual meeting, and they are under review by both associations for endorsement.

Women Abused During Childhood Have Significantly Higher Risk of Lupus

According to research presented at the annual meeting, women who experienced physical or emotional abuse in childhood have a significantly higher risk of developing systemic lupus erythematosus (SLE) in adulthood.

Treatment of Patients with AS, PsA, and PsO

During the annual meeting, a standing-room-only audience attended a product theater on Cosentyx® (secukinumab), manufactured by Novartis, which is used to treat several forms of spondyloarthritis.

A Divorce Between Psoriatic Arthritis and Rheumatoid Arthritis

At a dinner symposium hosted by Novartis at the annual meeting, a panel of experts explained the irreconcilable differences between psoriatic arthritis (PsA) and rheumatoid arthritis (RA).

Day 3

Secukinumab Improves Signs, Symptoms, and Physical Function in Ankylosing Spondylitis

According to data made available at the annual meeting, secukinumab (SEC) 150 mg provides sustained improvement in signs, symptoms, and physical function for patients with active ankylosing spondylitis (AS) through four years of treatment.

Secukinumab Provides Sustained Improvements in Psoriatic Arthritis

New data presented at the annual meeting show that secukinumab (SEC) provided sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) through five years of treatment.

Patients with Lupus Experienced Fewer Pregnancy Complications in Past 20 Years

Systemic lupus erythematosus (SLE) is a chronic disease that causes systemic inflammation and affects multiple organs. The condition is far more common in women than in men, and pregnancy in women with lupus has long been considered a high risk for medical and obstetric complications.

Physical Therapy or Surgery Provide Long-Term Pain Relief in Patients with Meniscal Tear and...

New research indicates that patients with meniscal tear and osteoarthritic changes in the knee can achieve similar pain improvement in the long term whether they receive arthroscopic partial meniscectomy (APM) or physical therapy (PT).

Genetic Risk Score May Identify Ankylosing Spondylitis Earlier

At the annual meeting, a team of researchers presented a new method to accurately assist in the early diagnosis of ankylosing spondylitis (AS). Their study found that a genetic risk score can help clinicians identify the condition earlier and at lower cost than current testing methods.

IQ-Lupus Program Decreases Hospitalizations Among High-Risk Patients

Systemic lupus erythematosus (SLE), or lupus, is a chronic disease that causes systemic inflammation and affects multiple organs, including kidneys, lung, heart, and brain, as well as the skin and joints.

Day 2

Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis:...

According to 52-week study results presented at the annual meeting, subcutaneous secukinumab (SEC) provided sustained inhibition of radiographic progression in patients with active psoriatic arthritis.

Research Finds Low Immunogenicity with Secukinumab in Patients with Psoriatic Arthritis or Ankylosing Spondylitis

Results from a new study presented at the 2018 annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals indicated that treatment with secukinumab (SEC) was associated with a low incidence of immunogenicity over 52 weeks in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS), similar to results seen in patients with plaque psoriasis.

Online Campaign Boosts Awareness of Lupus Among At-Risk Populations

Online resource help increase awareness in at-risk patient populations, according to results from a new study presented by the researchers at the 2018 annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals.

Children with Arthritis and Adverse Childhood Experiences Have Higher Rates of Depression, Anxiety, and...

Children with juvenile idiopathic arthritis (JIA) have a higher prevalence of adverse childhood experiences, according to new research presented at the annual meeting. In addition, children with JIA who have adverse childhood experiences are more likely to experience depression, anxiety, and physical impairment.

Research Identifies Independent Risk Factor for Mortality in Patients with Gout

According to research presented at the annual meeting, patients with gout who fail to reach a serum urate target of 6 mg/dL have a higher risk for mortality. The presenters encouraged rheumatologists to “treat to target” in patients with gout in order to improve chances of survival.

American College of Rheumatology Prepares Guideline on Reproductive Health in Rheumatic Disease

At its annual meeting, the American College of Rheumatology (ACR) presented a draft of a clinical practice guideline to help rheumatologists and obstetricians/gynecologists manage the reproductive health of patients with rheumatic disease.

Day 1

Data Show Efficacy of Secukinumab in Multiple Aspects of Ankylosing Spondylitis After 5 Years

At the annual meeting, researchers led by Xenofon Baraliakos, MD, of the Ruhr-University of Bochum in Germany, presented long-term, end-of-study findings from the phase III MEASURE 1 extension trial, which is evaluating the safety and efficacy of secukinumab (SEC) in patients with ankylosing spondylitis (AS).

Research Shows Secukinumab Is Effective in the Long Term Against Signs and Symptoms of...

At the annual meeting, a group of researchers led by Iain B. McInnes, MBChB, MRCP, PhD, of the University of Glasgow in the United Kingdom, presented long-term data from a phase III study evaluating the safety and efficacy of secukinumab (SEC) for active psoriatic arthritis (PsA).

Questions to Consider When Collecting Patient-Generated Data

Prior to the start of the annual meeting, an afternoon of presentations focused on “Applications of Mobile Health Technologies.”

The PROMIS of Measuring Patient-Reported Outcomes

A pre-meeting session at the annual meeting delved into the benefits and challenges of “PROMIS Versus Legacy Data Instruments” in collecting patient-reported outcomes (PROs) in rheumatology.

De-Hyping Artificial Intelligence and Machine Learning in Health Care

Prior to the annual meeting, the ACR Clinical Research Conference focused on technology advances that are changing the landscape of medicine and rheumatology. Beyond electronic health records, there is a broad range of digital and mobile technologies.

Making Medication Adherence “the Fifth Vital Sign”

During an afternoon of specialized pre-meeting sessions at the annual meeting, speakers addressed various aspects of health technology. One presenter, Bernard Vrijens, PhD, of AARDEX Group, stressed to attendees that “Medication Adherence Is a Key Element to Integrate in e-Health.”
Advertisement